Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 20;9(4):5038-5045.
doi: 10.1021/acsomega.3c09474. eCollection 2024 Jan 30.

Electrochemical HPLC Determination of Piperazine Antihistamine Drugs Employing a Spark-Generated Nickel Oxide Nanoparticle-Modified Carbon Fiber Microelectrode

Affiliations

Electrochemical HPLC Determination of Piperazine Antihistamine Drugs Employing a Spark-Generated Nickel Oxide Nanoparticle-Modified Carbon Fiber Microelectrode

Zeynab Belbasi et al. ACS Omega. .

Abstract

In this work, we demonstrate a sensitive high-performance liquid chromatography (HPLC) method for the determination of piperazine antihistamine drugs employing innovative electrochemical detection based on a spark-generated nickel oxide nanoparticle-modified carbon fiber microelectrode built into a miniaturized electrochemical detector. The direct carbon fiber-to-nickel plate electrode spark discharge, carried at 0.8 kV DC, with the nickel electrode connected to the negative pole of the high-voltage power supply, provides extremely fast (1 s) in situ tailoring of the carbon fiber microelectrode surface by nickel oxide nanoparticles. It has been found that nickel oxide nanoparticles exhibit an electrocatalytic effect toward the piperazine moiety electrooxidation process, as confirmed by voltammetric experiments, revealing the shift in the peak potential from 1.25 to 1.09 V versus Ag/AgCl. Cetirizine, cyclizine, chlorcyclizine, flunarizine, meclizine, and buclizine were selected as sample piperazine antihistamine drugs, while diclofenac served as an internal standard. The isocratic reversed-phase separation of the above set was achieved within 15 min using an ARION-CN 3 μm column with a binary mobile phase consisting of 50 mM phosphate buffer (pH 3) and methanol (45/55, v/v). The limits of detection (LOD) were within the range of 3.8-120 nM (for cyclizine and buclizine) at E = +1500 mV (vs Ag/AgCl), while the response was linear within the concentration range measured up to 5 μmol L-1. The method was successfully applied to the determination of piperazine antihistamine drugs in spiked plasma samples.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Chemical structures of the studied antihistamine drugs and of the diclofenac internal standard.
Figure 2
Figure 2
SEM images of bare carbon fibers (A), carbon-sparked carbon fibers (B), and nickel-sparked carbon fibers (C). Section of Ni-sparked carbon fiber (D) used for EDX mapping of nickel (E). Spark discharge modification procedure (F) and spark-modified CFME installed in the HPLC capillary (0.005’’ I.D.) outlet (G).
Figure 3
Figure 3
Cyclic voltammograms of 1 mM cetirizine in 0.05 M dihydrogen phosphate (pH = 3), recorded on (A) CFMEs and (B) SPEs, a: plain, b: C-sparked, and c: Ni-sparked under ambient conditions. Scan d: Ni-sparked SPE was under an argon atmosphere. Scan rate: 100 mV/s.
Figure 4
Figure 4
(A) Chromatogram of analytes with an internal standard under selected experimental conditions (mobile phase 50 mM NaH2PO4 (pH 3)/MeOH (45/55, v/v); Eapplied = 1500 mV, cAHs,IS = 5 × 10–6 mol L–1) and (B) corresponding hydrodynamic voltammograms of all studied drugs and IS, c = 7 μM each).
Figure 5
Figure 5
Chromatogram of plasma spiked with analytes and an internal standard (cCZ,CCZ,IS = 2 × 10–7 mol L–1, cCTZ = 5 × 10–7 mol L–1, cFLZ,MCZ = 8 × 10–7 mol L–1, cBCZ = 2 × 10–6 mol L–1) shown along with the blank plasma (gray trace). For chromatographic conditions, see the legend of Figure 4.

Similar articles

References

    1. Estelle F.; Simons R. Advances in H1-Antihistamines. N. Engl. J. Med. 2004, 351 (21), 2203–2217. 10.1056/NEJMra033121. - DOI - PubMed
    1. Hoyte F. C. L.; Katial R. K. Antihistamine Therapy in Allergic Rhinitis. Immunol. Allergy Clin. North Am. 2011, 31 (3), 509–543. 10.1016/j.iac.2011.05.003. - DOI - PubMed
    1. Mahdy A. M.; Webster N. R. Histamine and antihistamines. Anaesth. Intensive Care Med. 2017, 18 (4), 210–215. 10.1016/j.mpaic.2017.01.007. - DOI
    1. Raikar P.; Gurupadayya B.; Koganti V. S. Recent Advances in Chiral Separation of Antihistamine Drugs: Analytical and Bioanalytical Methods. Curr. Drug Delivery 2018, 15 (10), 1393–1410. 10.2174/1567201815666180830100015. - DOI - PubMed
    1. Cui Y.; Su A.; Feng J.; et al. Development of silica molecularly imprinted polymer on carbon dots as a fluorescence probe for selective and sensitive determination of cetirizine in saliva and urine. Spectrochim. Acta, Part A 2022, 264, 12029310.1016/j.saa.2021.120293. - DOI - PubMed

LinkOut - more resources